Business
Notice of Results and Investor Presentation
Futura Medical PLC will release its interim results for the six months ended June 30, 2025, on Tuesday, September 30, 2025. Management will host a webinar via the Investor Meet Company platform on September 30, 2025, at 09.30am BST to discuss the results. The presentation is open to all existing and potential shareholders, who can submit questions in advance until 9.00am BST the day before or during the live presentation. Interested parties can register for the presentation through a provided link. Disclaimer*
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n26 September 2025\n \nFutura Medical plc\n(\"Futura\" or the \"Company\")\nNotice of Results & Investor Presentation\nFutura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, will release its interim results for the six months ended 30 June 2025 on Tuesday 30 September.\n \nManagement will be hosting a webinar relating to the results via the Investor Meet Company platform on 30 September 2025, at 09.30am BST.\n \nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am BST the day before, or at any time during the live presentation.\n \nInvestors can register for the presentation via the following link: https://www.investormeetcompany.com/futura-medical-plc/register-investor. Investors who already follow Futura on the Investor Meet Company platform will automatically be invited.\n \n \nContacts:\n\n\n\n\nFutura Medical plc\n \n \n \n\n\nAlex Duggan\nInterim Chief Executive Officer\nAngela Hildreth\nFinance Director and COO\n \n\n\[email protected]\n+44 (0)1483 685 670\nwww.futuramedical.com\n \n\n\n\n\nPanmure Liberum\nNominated Adviser\nand Broker\n \n\n\nEmma Earl, Will Goode,\nMark Rogers (Corporate Finance)\nRupert Dearden (Corporate Broking)\n\n\n+44 (0)20 3100 2000\n \n \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nAlma Strategic Communications\n\n\nRebecca Sanders-Hewett\nSam Modlin\nEmma Thompson\n\n\n+44 (0)20 3405 0205\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nNotes to Editors:\nFutura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and new products in development WSD4000 and Eroxon® Intense. The Company's core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.\nSexual health issues are prevalent in both men and women. Erectile dysfunction (ED) impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in ...